Treatments

Main Content

COVID-19 Monoclonal Antibody (mAb) Treatment

If you are a UMMC patient interested in monoclonal antibody (mAb) treatment, please consult your UMMC provider for a referral.

To qualify for treatment, UMMC patients must:

  • Have tested positive for COVID-19
  • Be within 10 days from beginning of symptoms
  • Be at least 12 years old and weigh at least 88 pounds
  • Have mild to moderate symptoms, such as fever, cough, or shortness of breath
  • Be at high risk of getting worse

About Monoclonal Antibody (mAb) Treatment
The FDA has approved the REGEN-COV™ (casirivimab/imdevimab) monoclonal antibody treatment for some adults and children with mild to moderate COVID-19. When started early in the disease, treatment with antibodies may help keep people from getting worse. The treatment is not approved for cases that have advanced past the mild to moderate stage, so it’s important to begin treatment as soon as possible.

What to expect during treatment
The antibodies are given in shots or IVs. Treatment does not require admission to the hospital. This will take up to three hours. This includes preparation for treatment, the treatment itself, and time to observe you after treatment.

Note: Monoclonal antibody treatments should not be used for patients who are hospitalized with COVID-19, require oxygen therapy for COVID-19, or have an increase in baseline oxygen flow rate due to COVID-19.